U.S. intelligence agencies believe that North Korea has increased its production of fuel for nuclear weapons at multiple secret sites in recent months, NBC reported, citing unidentified American officials.
The NBC report quoted U.S. officials who said they believe that North Korean leader Kim Jong Un may try to hide those facilities as he seeks more concessions in nuclear talks with the Trump administration.
Top 10 Stocks For 2019: PAR Technology Corporation(PAR)
Advisors' Opinion:- [By Max Byerly]
News articles about PAR Technology (NYSE:PAR) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PAR Technology earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the software maker an impact score of 46.8901065500531 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Top 10 Stocks For 2019: Ultragenyx Pharmaceutical Inc.(RARE)
Advisors' Opinion:- [By Shane Hupp]
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
- [By Todd Campbell]
A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that's successfully developed drugs for rare diseases.
- [By Joseph Griffin]
BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.
A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.
- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
Top 10 Stocks For 2019: Fiesta Restaurant Group, Inc.(FRGI)
Advisors' Opinion:- [By Demitrios Kalogeropoulos]
Fiesta Restaurant Group�(NASDAQ:FRGI), home of the Pollo Tropical and Taco Cabana fast-casual chains, is back in Wall Street's good graces after a tough 2017 that was marked by falling sales at existing locations and an overall net loss. Its rebound plan, which includes cost cuts, menu improvements, and increased marketing investments, appears to be working. Sales returned to modest growth in the Pollo Tropical segment and are looking better at Taco Cabana. Those gains represent just the first small step in bringing the business back toward the nearly 10% operating margin shareholders saw in 2015, up from roughly 3% today.�
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Fiesta Restaurant Group (FRGI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin] Gainers Integrated Media Technology Limited (NASDAQ: IMTE) rose 30.8 percent to $22.00 in pre-market trading after declining 18.63 percent on Monday. Nevsun Resources Ltd. (NYSE: NSU) rose 14.5 percent to $3.40 in pre-market trading after Lundin Mining Corporation and Euro Sun Mining Inc. proposed to acquire Nevsun Resources for around C$1.5 billion. Sharing Economy International Inc. (NASDAQ: SEII) rose 15.2 percent to $4.25 in pre-market trading after the company disclosed that it entered into a license agreement with Ecrent Capital Holdings Limited. Veeco Instruments Inc. (NASDAQ: VECO) shares rose 14.1 percent to $19.50 in pre-market trading after reporting stronger-than-expected earnings for its first quarter. Impinj, Inc. (NASDAQ: PI) rose 13.4 percent to $15.40 in pre-market trading after reporting Q1 results. SandRidge Energy, Inc. (NYSE: SD) shares rose 13.2 percent to $16.45 in pre-market trading following Q1 results. Blink Charging Co. (NASDAQ: BLNK) rose 12.6 percent to $4.55 in pre-market trading after jumping 171.14 percent on Monday. Crocs, Inc. (NASDAQ: CROX) shares rose 10 percent to $16.66 in pre-market trading after the company reported better-than-expected earnings for its first quarter and issued strong sales forecast for the second quarter. Pareteum Corporation (NASDAQ: TEUM) rose 9.7 percent to $3.05 in pre-market trading after announcing Q1 results. Dean Foods Company (NYSE: DF) rose 8 percent to $9.00 in pre-market trading after reporting upbeat Q1 earnings. Fiesta Restaurant Group, Inc. (NASDAQ: FRGI) rose 7.3 percent to $23.45 in pre-market trading following Q1 results. IAMGOLD Corporation (NYSE: IAG) rose 7.1 percent to $6.09 in pre-market trading after reporting upbeat Q1 earnings. TC PipeLines, LP (NYSE: TCP) rose 6.4 percent to $27 in pre-market trading after gaining 2.08 percent on Monday. Carrols Restaurant Group, Inc. (NASDAQ: TAST) rose 6.3 percent to $11.75 in pre-market trading fol
- [By Lisa Levin] Gainers ProPhase Labs, Inc. (NASDAQ: PRPH) gained 50.7 percent to $4.34 after the company announced a special $1.00 per share cash dividend. Impinj, Inc. (NASDAQ: PI) surged 28.4 percent to $17.44 after reporting Q1 results. Cardlytics, Inc. (NASDAQ: CDLX) gained 22 percent to $17.945. Care.com, Inc. (NYSE: CRCM) shares rose 19.3 percent to $18.92 following Q1 earnings. Sharing Economy International Inc. (NASDAQ: SEII) jumped 19.1 percent to $4.3934 after the company disclosed that it entered into a license agreement with Ecrent Capital Holdings Limited. Blink Charging Co. (NASDAQ: BLNK) rose 18.6 percent to $4.79 after jumping 171.14 percent on Monday. IntriCon Corporation (NASDAQ: IIN) climbed 17.4 percent to $29.30 after reporting Q1 results. Nevsun Resources Ltd. (NYSE: NSU) rose 16.2 percent to $3.45 after Lundin Mining Corporation and Euro Sun Mining Inc. proposed to acquire Nevsun Resources for around C$1.5 billion. Tactile Systems Technology, Inc. (NASDAQ: TCMD) gained 15.4 percent to $42.61 following Q1 results. eGain Corporation (NASDAQ: EGAN) gained 15.3 percent to $10.55 following Q3 earnings. Dean Foods Company (NYSE: DF) rose 13.8 percent to $9.48 after reporting upbeat Q1 earnings. Sterling Construction Company, Inc. (NASDAQ: STRL) shares surged 13.1 percent to $13.42 after reporting Q1 results. USA Technologies, Inc. (NASDAQ: USAT) climbed 11.9 percent to $10.85 following better-than-expected Q3 earnings. scPharmaceuticals Inc. (NASDAQ: SCPH) gained 11.2 percent to $14.45 following Q1 results. Fiesta Restaurant Group, Inc. (NASDAQ: FRGI) rose 10.2 percent to $24.08 following Q1 results. Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 7.9 percent to $19.60 as the company posted upbeat Q1 results and raised its outlook. Carrols Restaurant Group, Inc. (NASDAQ: TAST) rose 7.7 percent to $11.90 following upbeat Q1 results. Pareteum Corporation (NASDAQ: TEUM) rose 6.8 perc
- [By Jeremy Bowman]
Shares of�Fiesta Restaurant Group Inc.�(NASDAQ:FRGI) were moving higher today after the parent of fast-casual chains Pollo Tropical and Taco Cabana posted better-than-expected results in its first-quarter earnings report. Margins improved at Pollo Tropical, and comparable sales increased at both chains in April after the quarter ended.
Top 10 Stocks For 2019: Chuy's Holdings, Inc.(CHUY)
Advisors' Opinion:- [By Shane Hupp]
Arcos Dorados (NYSE: ARCO) and Chuy’s (NASDAQ:CHUY) are both small-cap retail/wholesale companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
- [By Ethan Ryder]
Papa Murphy’s (NASDAQ: FRSH) and Chuy’s (NASDAQ:CHUY) are both small-cap retail/wholesale companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
- [By Dan Caplinger]
As an investor, it's always hard when a company you love doesn't see things go its way. I ate at Tex-Mex chain Chuy's Holdings (NASDAQ:CHUY) original Austin locations hundreds of times during my time in Texas' capital city, and eating at not one but two of its Houston-area restaurants on a recent trip to my hometown was a highlight of my time there. Yet despite my own contributions toward boosting Chuy's sales performance, the company's broader fortunes have remained mixed, and a brutally competitive restaurant industry has made it hard for Chuy's to keep itself moving forward despite its ambitious expansion efforts.
- [By Max Byerly]
Chuy’s (NASDAQ:CHUY) CEO Steven J. Hislop sold 3,690 shares of the company’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $30.00, for a total transaction of $110,700.00. Following the completion of the transaction, the chief executive officer now owns 132,460 shares in the company, valued at approximately $3,973,800. The sale was disclosed in a legal filing with the SEC, which is available through this link.
- [By Motley Fool Staff]
Chuy's Holdings (NASDAQ:CHUY) Q1 2018 Earnings Conference CallMay. 8, 2018 4:30 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 10 Stocks For 2019: Nuveen Core Equity Alpha Fund(JCE)
Advisors' Opinion:- [By Ethan Ryder]
Nuveen Core Equity Alpha Fund (NYSE:JCE) announced a quarterly dividend on Monday, June 4th, Wall Street Journal reports. Shareholders of record on Friday, June 15th will be paid a dividend of 0.2775 per share on Monday, July 2nd. This represents a $1.11 dividend on an annualized basis and a yield of 7.36%. The ex-dividend date of this dividend is Thursday, June 14th.
- [By Max Byerly]
Shaker Financial Services LLC lessened its holdings in shares of Nuveen Core Equity Alpha (NYSE:JCE) by 70.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 46,154 shares of the company’s stock after selling 112,257 shares during the period. Shaker Financial Services LLC’s holdings in Nuveen Core Equity Alpha were worth $674,000 at the end of the most recent reporting period.
Top 10 Stocks For 2019: NovoCure Limited(NVCR)
Advisors' Opinion:- [By Chris Lange]
Novocure Ltd. (NASDAQ: NVCR) announced results from its Phase 3 INNOVATE trial of TTFields in platinum-resistant ovarian cancer. There were no major surprises, except study size is larger than some investors expected, which is not concerning. INNOVATE-3 is set to start later this year and as previously announced will enroll patients with recurrent platinum-resistant ovarian cancer.
- [By Ethan Ryder]
NovoCure (NASDAQ:NVCR) Director Gabriel Leung sold 80,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $28.83, for a total value of $2,306,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
- [By Chris Lange]
NocoCure Ltd. (NASDAQ: NVCR) is scheduled to release its fourth-quarter earnings report on February 22 as well. The consensus estimates call for a net loss of $0.11 per share and $53.52 million in revenue. The same period of last year had a net loss of $0.26 per share and $30.24 million in revenue. Shares of Novocure most recently closed at $21.50, with a consensus price target of $27.00 and a 52-week range of $6.75 to $24.15.
Top 10 Stocks For 2019: KAR Auction Services, Inc(KAR)
Advisors' Opinion:- [By Lisa Levin]
Companies Reporting After The Bell Marriott International, Inc. (NASDAQ: MAR) is projected to post quarterly earnings at $1.22 per share on revenue of $5.72 billion. Electronic Arts Inc. (NASDAQ: EA) is estimated to post quarterly earnings at $1.04 per share on revenue of $5.68 billion. The Walt Disney Company (NYSE: DIS) is projected to post quarterly earnings at $1.68 per share on revenue of $14.05 billion. Papa John's International, Inc. (NASDAQ: PZZA) is expected to post quarterly earnings at $0.62 per share on revenue of $441.73 million. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post quarterly earnings at $2.77 per share on revenue of $434.87 million. Sun Life Financial Inc. (NYSE: SLF) is estimated to post quarterly earnings at $0.89 per share on revenue of $6.38 billion. LATAM Airlines Group S.A. (NYSE: LTM) is expected to post quarterly earnings at $0.16 per share on revenue of $2.70 billion. Liberty Global plc (NASDAQ: LBTYA) is projected to post quarterly earnings at $0.02 per share on revenue of $4.05 billion. TripAdvisor, Inc. (NASDAQ: TRIP) is expected to post quarterly earnings at $0.16 per share on revenue of $362.11 million. The Wendy's Company (NASDAQ: WEN) is projected to post quarterly earnings at $0.1 per share on revenue of $379.98 million. A-Mark Precious Metals, Inc. (NASDAQ: AMRK) is expected to post quarterly earnings at $0.06 per share on revenue of $1.69 billion. Monster Beverage Corporation (NASDAQ: MNST) is estimated to post quarterly earnings at $0.4 per share on revenue of $849.38 million. Convergys Corporation (NYSE: CVG) is expected to post quarterly earnings at $0.4 per share on revenue of $670.10 million. ScanSource, Inc. (NASDAQ: SCSC) is projected to post quarterly earnings at $0.7 per share on revenue of $875.91 million. KAR Auction Services, Inc. (NYSE: KAR) is expected to post quarterly earnings at $0.76 per share on revenue of $923.13 - [By Max Byerly]
KAR Auction Services, Inc. (NYSE:KAR) – Equities researchers at Northcoast Research reduced their Q3 2018 EPS estimates for shares of KAR Auction Services in a research report issued on Wednesday, May 9th. Northcoast Research analyst J. Healy now expects that the specialty retailer will post earnings of $0.72 per share for the quarter, down from their previous forecast of $0.73.
- [By Joseph Griffin]
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
Get KAR Auction Services alerts: ADESA to auction off 2018 Honda Accord to benefit NIADA Foundation (autoremarketing.com) Donald S. Gottwald Sells 10,000 Shares of KAR Auction Services Inc (KAR) Stock (americanbankingnews.com) KAR Auction Services Inc (KAR) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com) ADESA Canada Names New Vice President of Dealer Sales (finance.yahoo.com) ADESA announces 2 newly promoted Chicago, Fresno GMs (autoremarketing.com)A number of brokerages have issued reports on KAR. Barrington Research reiterated a “buy” rating on shares of KAR Auction Services in a report on Monday, May 7th. Robert W. Baird reiterated a “buy” rating and issued a $60.00 price target on shares of KAR Auction Services in a report on Thursday, March 1st. Gabelli upgraded shares of KAR Auction Services from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Guggenheim began coverage on shares of KAR Auction Services in a report on Tuesday, April 17th. They issued a “neutral” rating on the stock. Finally, ValuEngine downgraded shares of KAR Auction Services from a “buy” rating to a “hold” rating in a report on Saturday, June 2nd. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. KAR Auction Services presently has an average rating of “Buy” and an average price target of $58.78.
Top 10 Stocks For 2019: Mueller Industries, Inc.(MLI)
Advisors' Opinion:- [By Ethan Ryder]
Swiss National Bank grew its position in shares of Mueller Industries, Inc. (NYSE:MLI) by 3.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,400 shares of the industrial products company’s stock after buying an additional 3,100 shares during the period. Swiss National Bank owned about 0.17% of Mueller Industries worth $2,496,000 as of its most recent SEC filing.
Top 10 Stocks For 2019: Blueprint Medicines Corporation(BPMC)
Advisors' Opinion:- [By Todd Campbell]
After clinical-stage competitor Loxo Oncology (NASDAQ:LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ:BPMC) tumbled by as much as 16% on Monday.
- [By Stephan Byrd]
Fernwood Investment Management LLC lessened its holdings in shares of Blueprint Medicines (NASDAQ:BPMC) by 29.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,696 shares of the biotechnology company’s stock after selling 1,120 shares during the period. Fernwood Investment Management LLC’s holdings in Blueprint Medicines were worth $247,000 at the end of the most recent reporting period.
- [By Shane Hupp]
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC acquired a new position in Blueprint Medicines in the 4th quarter valued at about $173,000. First Mercantile Trust Co. acquired a new position in Blueprint Medicines in the 4th quarter valued at about $183,000. Tower Research Capital LLC TRC grew its position in Blueprint Medicines by 942.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new position in Blueprint Medicines in the 4th quarter valued at about $227,000. 97.79% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades Blueprint Medicines (BPMC) to Hold” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3356624/bidaskclub-downgrades-blueprint-medicines-bpmc-to-hold.html.Blueprint Medicines Company Profile
- [By Todd Campbell]
The big thing to watch this week will be how investors view Loxo's results in comparison to results presented earlier this year by Blueprint Medicines (NASDAQ:BPMC). Blueprint's BLU-667 also targets RET-fusions and at the American Association for Cancer Research meeting in April, Blueprint revealed a preliminary overall response rate of 50% for NSCLC and 40% for MTC. It's bad science to compare unrelated trials, so investors might be best off viewing Loxo and Blueprint's data as evidence that they're both working on a winning approach.
- [By Todd Campbell]
In this clip of The Motley Fool's Industry Focus Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss LOXO-292's opportunity and how competitor Blueprint Medicines (NASDAQ:BPMC) is challenging it. Also, the two analysts discuss why shares in Abiomed, Inc. (NASDAQ:ABMD) are soaring higher and if this is a high-priced stock that investors should embrace or ignore.
- [By Ethan Ryder]
Northern Trust Corp boosted its position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 497,135 shares of the biotechnology company’s stock after acquiring an additional 726 shares during the period. Northern Trust Corp owned 1.13% of Blueprint Medicines worth $45,588,000 at the end of the most recent quarter.
Top 10 Stocks For 2019: Atlantic Coast Federal Corporation(ACFC)
Advisors' Opinion:- [By Ethan Ryder]
Atlantic Coast Financial (NASDAQ: ACFC) and People’s United Financial (NASDAQ:PBCT) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
No comments:
Post a Comment